DRG Epidemiology’s coverage of vitiligo comprises epidemiological estimates of key patient populations in 45 countries. We report the diagnosed prevalence of vitiligo for each country, as well as…
MARKET OUTLOOK NASH is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of diabetes and…
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 400 currently available and novel biosimilar products, detailing…
Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal…
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,…
MARKET OUTLOOK China has the highest incidence of gastric cancer (gastric and gastroesophageal junction adenocarcinoma) in the world, and therapeutic options are limited. Only two targeted agents…
The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the…
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was…
MARKET OUTLOOK With the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (…
MARKET OUTLOOKWith the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma— continues to rise; however, treatment options remain…
Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment has been dominated by…
DRG anticipates the next ten years to be a transitional time in the treatment of hemophilia A for patients with and without inhibitors. With the uptake of Roche / Chugai’s bispecific antibody…